Abstract：Objective To study the difference in expression of TOPK/PBK in lymph nodes between children with malignant lymphoma and those with reactive lymphoid hyperplasia. Methods Eighty children with malignant lymphoma and twenty children with reactive lymphoid hyperplasia were enrolled as subjects. Immunohistochemistry was used to determine the expression of TOPK/PBK in all the subjects. The expression of TOPK/PBK was compared between the two groups. Results The TOPK/PBK-positivity rate was significantly higher in children with malignant lymphoma than in those with reactive lymphoid hyperplasia (P < 0.05). There was no significant difference in the TOPK/PBK-positivity rate between the children with Hodgkin's lymphoma and non-Hodgkin's lymphoma (NHL). There were significant differences in the TOPK/PBK-positivity rate among children with different pathological types of NHL (P < 0.05):the children with lymphoblastic lymphoma showed the highest TOPK/PBK-positivity rate and those with mature B-cell lymphoma and mature T/NK-cell lymphoma had a similar TOPK/PBK-positivity rate. Conclusions The expression of TOPK/PBK is up-regulated in the lymph nodes of children with malignant lymphoma. The expression level of TOPK/PBK may be related to the pathological type of NHL.
TIAN Xin,HE Xiang-Ling,YUAN Xiao-Ye et al. Expression of TOPK/PBK in children with malignant lymphoma or reactive lymphoid hyperplasia[J]. CJCP, 2018, 20(3): 214-217.
Ramirez-Avila L, Garner OB, Cherry JD. Relative EBV antibody concentrations and cost of standard IVIG and CMV-IVIG for PTLD prophylaxis in solid organ transplant patients[J]. Pediatr Transplant, 2014, 18(6):599-601.
[2]
Raab-Traub N. Novel mechanisms of EBV-induced oncogenesis[J]. Curr Opin Virol, 2012, 2(4):453-458.
[3]
Hall LD, Eminger LA, Hesterman KS, et al. Epstein-Barr virus:dermatologic associations and implications:part I. Mucocutaneous manifestations of Epstein-Barr virus and nonmalignant disorders[J]. J Am Acad Dermatol, 2015, 72(1):1-19.
[4]
Iwakiri D. Mechanisms of Epstein-Barr virus-mediated oncogenesis[J]. Gan To Kagaku Ryoho, 2015, 42(10):1133-1136.
Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J]. Blood, 2016, 127(20):2391-2405.
[7]
Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes[J]. Science, 2013, 339(6127):1546-1558.
[8]
Simons-Evelyn M, Bailey-Dell K, Toretsky JA, et al. PBK/TOPK is a novel mitotic kinase which is upregulated in Burkitt's lymphoma and other highly proliferative malignant cells[J]. Blood Cells Mol Dis, 2001, 27(5):825-829.
[9]
Nandi A, Tidwell M, Karp J, et al. Protein expression of PDZ binding kinase is up-regulated in hematologic malignancies and strongly down regulated during terminal differentiation of HL-60 leukemic cells[J]. Blood Cells Mol Dis, 2004, 32(1):240-245.
